Friday May 16, 09:28 AM
Northwest Biotherapeutics Q1 loss widens on higher operating expenses
LONDON (Thomson Financial) - Northwest Biotherapeutics Inc (NWBT.OB - news) . said its first-quarter loss widened due to higher operating expenses, including research and development costs and administrative expenses.
The U.S.-based biotech company said for the first quarter ended March, its net loss widened to $5.63 million from $1.95 million, while operating expenses increased to $5.69 million from $1.82 million, a year ago.
The company's research and development costs increased to $3.06 million from $1.31 million, and general and administrative expenses grew to $2.63 million from $511,000.
|
|
|
Send Article by Email
Send Article by IM
Blog This with Y! 360
Printable View
